JAMA Network
About The Study: In this randomized clinical trial, clesrovimab, a long-acting monoclonal antibody, was well tolerated in infants at increased risk for severe respiratory syncytial virus (RSV) disease through 2 RSV seasons. These findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
